Laura Umbrecht Gulick

Laura Umbrecht Gulick is a partner at Goodwin. Laura regularly represents public and private pharmaceutical, biotechnology, pharma services, and medical device companies and their investors in connection with complex corporate transactions, including mergers and acquisitions, leveraged buyouts, reverse mergers, de-SPAC transactions asset purchases and divestitures as well as joint ventures, carve-out transactions, equity financings, co-investments and licensing, development, and collaboration transactions. She also advises clients on a variety of corporate governance and securities law matters.

Prior to joining Goodwin in 2023, Laura worked at two law firms in connection with a variety of transactions for public and private companies and private equity sponsors.

Laura’s Representative Matters include the following:

• Represented Human Immunology Biosciences (HI-Bio™) on its acquisition by Biogen for $1.15 billion upfront and up to $650 million in potential milestone payments
• Represented Mariana Oncology on its acquisition by Novartis for $1 billion upfront and up to $750 million in potential milestone payments
• Represented Globus Medical in its $3.1 billion merger with NuVasive, Inc.
• Represented Zynerba Pharmaceuticals, Inc. in its $200 million sale to Harmony Biosciences
• Represented Societal CDMO, Inc. in its $130 million sale to CoreRX, Inc.
• Represented AlmataBio in its reverse merger with Avalo Therapeutics and concurrent $185 million private placement
• Represented Akari Therapeutics in its definitive merger with Peak Bio Inc.
• Represented Century Therapeutics in its acquisition of Clade Therapeutics and its $60 private placement
• Represented ReWalk Robotics Ltd. in its acquisition of AlterG, Inc.
• Represented Baudax Bio in its acquisition of TeraImmune, Inc.
• Represented Verisma Systems in its acquisition of ScanSTAT Technologies
• Represented an early-stage biotechnology company in a reverse merger with a special purpose acquisition company and subsequent sale to a major American biotechnology company*
• Represented a leading diversified specialty pharmaceutical company in its acquisition of a NASDAQ-listed specialty pharma company specializing in pain drugs*
• Represented an American pharmaceutical company in its acquisition of a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration*
• Represented a clinical stage biopharmaceutical company developing immune-modulating therapies targeting cancer, ARS, inflammatory, and autoimmune diseases in its reverse merger with a biopharmaceutical company developing novel approaches to activating the immune system*
• Represented a contract development and manufacturing organization (CDMO) in its acquisition of a San Diego CDMO, for a combination of stock, cash, and promissory notes*
• Represented a global network of laboratories headquartered in Luxembourg in connection with its acquisition of a preeminent drug discovery and contract research organization focused on G-protein Coupled Receptor research*
• Represented a British multinational pharmaceutical company in its divestiture of certain product assets and in connection with various licensing, development, and collaboration matters with third party partners*
• Represented a global pharmaceutical company specializing in allergy immunotherapy products in its acquisition of certain pharmaceutical product assets*
• Represented a boutique contract development and manufacturing organization in its sale to a portfolio company of NovaQuest Private Equity*
• Represented a developer of advanced ferrofluid-based immunomagnetic cell selection platforms in its sale to a life sciences tools platform created by a global investment company*
• Represented a private equity investor in its acquisition of a clinical research technology and services company, and subsequent partial sale and co-investment in ERT*
• Represented an American private equity firm in its acquisition of an anatomic and clinical pathology laboratory services company, and subsequent strategic acquisitions*
• Represented a global institutional investment management firm in its $240 million acquisition of a trucking transportation and logistic services company, and subsequent strategic acquisitions*
• Represented a publicly traded media company in several transformative transactions including its $6.4 billion acquisition of an American multimedia conglomerate, its $1.3 billion sale of 19 television stations in fifteen markets to TEGNA inc. and The E.W. Scripps Company in simultaneous transactions, and its unsolicited takeover of a publicly listed major American media company*
• Represented a leading diversified technology company its agreement to sell its air and gas handling business to an American investment company*
• Represented the largest Spanish restaurant group in the US in its sale to an American steakhouse restaurant chain*

* Denotes experience prior to joining Goodwin

Laura has been named a 2024 Woman of Influence by the Philadelphia Business Journal. The annual list recognizes outstanding businesswomen who are making a significant impact in the Greater Philadelphia area.